A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes

PHASE4RecruitingINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Type2diabetes
Interventions
DRUG

Dorzagliatin tablets

During the study, patients should follow the dosing instructions from the investigator, which are made according to the package insert and the patients' conditions.

Trial Locations (2)

100029

RECRUITING

China-Japan Friendship Hospital, Beijing

RECRUITING

China-Japan Friendship Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Shanghai Branch, KunTuo Medical Research and Development (Beijing) Co., Ltd.

UNKNOWN

lead

Hua Medicine Limited

INDUSTRY